We are very proud to announce that our Fulvestrant injection (0.25g:5ml/Prefilled syringe) indicated to breast cancer, was approved by NMPA with market authorization No. H20223421, on June 28th 2022. Now international licensing is available worldwide.
In the mean time, our Semaglutide injection (indicated to diabetes)  has finished phase I clinical study in China and phase III study will be initiated very soon.